Sun Pharma Advanced Research Company

What Sun Pharma Advanced Research Company does

Sun Pharma Advanced Research Company Limited (SPARC) is a publicly listed (NSE: SPARC) clinical-stage biopharmaceutical company headquartered in Mumbai, India, operating as the dedicated innovation arm of Sun Pharmaceutical Industries Ltd. The company discovers and develops novel therapeutics in oncology and immunology, with a current pipeline of four clinical-stage assets: Vodobatinib (SCO-088), a selective BCR-ABL1 tyrosine kinase inhibitor for refractory chronic myeloid leukemia (Phase 2); SBO-154, an anti-MUC-1 SEA domain antibody-drug conjugate for multiple carcinomas (Phase 1, with INDs open in the US, Australia, and India); Vibozilimod (SCD-044), a 10,000-fold selective S1PR1 agonist for psoriasis and atopic dermatitis (Phase 2b); and SCD-153, a topical 4-methyl itaconate prodrug for alopecia areata (Phase 1b). The FDA-approved product Sezaby (phenobarbital sodium for neonatal seizures) is commercialized by parent Sun Pharma and generated a Rare Paediatric Disease Priority Review Voucher, which SPARC sold in April 2026 for USD 195 million.

SPARC operates an asset-light business model: it conducts discovery and clinical development internally through its Vadodara R&D center (200+ scientists across 42 labs on 46,000 sq.ft.) and a Princeton, US office, then out-licenses commercialization rights to established pharmaceutical partners, generating revenue through upfront payments, development and regulatory milestones, and royalties. Recurring revenue is therefore concentrated among a small set of partners (Sun Pharma, Tripoint Therapeutics, Visiox Pharma, plus in-licensors Bioprojet, Biomodifying, JHU, IOCB, and the new UCSF/Tiller collaboration). FY26 reported results show net profit of Rs 1,553.20 crore on consolidated Q4 sales of only Rs 13.20 crore, indicating that profitability is driven primarily by one-time, non-operational events (principally the PRV sale) rather than steady-state licensing economics.

In early 2026 the company announced a 40% workforce reduction (from 409 in FY24 to approximately 246 by FY27), consolidation of four laboratory sites into two, and a shift from a fully captive R&D model to a hybrid model that outsources selected functions to contract research organizations, targeting approximately USD 10 million in annual savings against USD 46 million of debt under a USD 125 million facility. Leadership transitions in mid-2026 include the retirements of the COO and the Functional Head of Human Resources. These actions, together with the May 2026 Rs 149.99 crore warrant issuance to promoter-group entity Shanghvi Finance, indicate a deliberate restructuring to extend capital runway, prioritize a narrower pipeline of higher-conviction programs, and rely increasingly on milestone-based economics from licensing partners.

Name

Sun Pharma Advanced Research Company

Legal name

Sun Pharma Advanced Research Company Limited

Website

https://sparc.life

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SPARC is a publicly listed, clinical-stage biopharmaceutical company (NSE: SPARC) and innovation arm of Sun Pharma that develops novel oncology and immunology therapeutics and out-licenses commercialization to pharmaceutical partners for milestone and royalty revenue.

Ownership category

akta.pro rank

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Licensing and Royalty Revenue: SPARC develops proprietary drug candidates and out-licenses commercialization rights to pharmaceutical partners. Revenue comes from upfront payments, milestone payments, and ongoing royalties on product sales.
2. Priority Review Voucher Sale: SPARC sold its Rare Paediatric Disease Priority Review Voucher (PRV) for USD 195 million in April 2026. The PRV was granted by US FDA in connection with approval of Sezaby for neonatal seizures.
3. Milestone Payments: Revenue from development and regulatory milestones as drug candidates progress through clinical trials and receive approvals. Examples include Sezaby FDA approval in November 2022.
4. Product Sales (Standalone): Standalone Q4 March 2026 net sales at Rs 1,853.22 crore (significant increase due to one-time gains). However, sales declined 51.45% to Rs 13.20 crore in consolidated results, suggesting core revenue is limited and profit derived from non-operational gains.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

SPARC is a clinical-stage biopharmaceutical company that discovers and develops innovative therapeutics in oncology and immunology. It advances proprietary drug candidates through clinical trials and out-licenses commercialization rights to established pharmaceutical partners. Its pipeline includes BCR-ABL inhibitors, anti-MUC-1 ADCs, and S1PR1 agonists targeting refractory CML, multiple tumors, psoriasis, atopic dermatitis, and alopecia areata.

Product overview

Sun Pharma Advanced Research Company (SPARC) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in oncology and immunology. The company operates a differentiated pipeline of drug candidates at various clinical stages: Vodobatinib (SCO-088) is a BCR-ABL inhibitor for refractory CML in Phase 2; SBO-154 is an Anti-MUC-1 ADC for multiple tumors in Phase 1; SCD-153 is a topical treatment for Alopecia Areata in Phase 1b. Additionally, Sezaby (phenobarbital sodium) received FDA approval in November 2022 for neonatal seizures and has been out-licensed to Sun Pharma. The company also maintains out-licensed products including PDP-716 (glaucoma, licensed to Visiox), SDN-037 (ocular surgery, licensed to Visiox), and Elepsia XR (epilepsy, licensed to Tripoint). SPARC has transitioned from a fully captive research model to a hybrid model, outsourcing some work to clinical research organizations.

Differentiator

Problem solved

Functional benefit

Products and services

• SEZABY (phenobarbital sodium powder for injection) US FDA-approved treatment for neonatal seizures developed by SPARC and commercialized through a license agreement with Sun Pharma.
• Vodobatinib (SCO-088) Novel and highly selective BCR-ABL tyrosine kinase inhibitor active in wild-type and mutant BCR-ABL1, being developed to treat resistant Chronic Myeloid Leukemia; Phase 2 clinical trials. Holds Orphan Drug Designation.
• SBO-154 (Anti-MUC-1 ADC) Novel MUC-1 SEA domain targeting antibody drug conjugate for treatment of multiple tumors including pancreatic, head and neck, and hormone refractory breast carcinomas; Phase 1 clinical trials.
• Vibozilimod (SCD-044) Highly selective second-generation S1P1 receptor-1 (S1PR1) agonist with 10,000-fold selectivity for S1PR1 over S1PR3 for treatment of psoriasis and atopic dermatitis; Phase 2b completed.
• SCD-153 (Topical 4-methyl itaconate prodrug) Topical 4-methyl itaconate prodrug for treatment of Alopecia Areata, an autoimmune disease causing hair loss; Phase 1b MAD study recruiting. Licensed from Johns Hopkins University and IOCB.
• PDP-716 (brimonidine) Out-licensed ophthalmic product for treatment of Open Angle Glaucoma or Ocular Hypertension; development and commercialization rights licensed to Visiox Pharma.
• SDN-037 (difluprednate) Out-licensed ophthalmic product for treatment of inflammation and pain associated with ocular surgery; development and commercialization rights licensed to Visiox Pharma.
• Elepsia XR (Levetiracetam ER Tablets) FDA-approved product for epilepsy treatment; commercialization rights licensed to Tripoint Therapeutics for 1000mg and 1500mg ER tablet formulations.

Quantifiable outcome

• SCO-088 achieved maximum tolerated dose of 204 mg once daily in Phase 1 study in CML patients failing 3+ prior TKI therapies
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Sun PharmacoreOEM/ Whitelabel/ Licensing Partner · 18 November 2022Sun Pharma and SPARC have multiple licensing agreements. Sun Pharma commercializes Sezaby (phenobarbital for neonatal seizures) in the US, and also received rights to Xelpros (for open-angle glaucoma). Sun Pharma Industries Ltd. conducted Phase 2b studies of Vibozilimod in psoriasis and atopic dermatitis.
• BiomodifyingcoreStrategic or Co-development PartnerSPARC entered into licensing agreement with Biomodifying to acquire exclusive rights for antibodies against unique oncology target (anti-MUC-1).
• BioprojetcoreStrategic or Co-development PartnerIn-licensed Vibozilimod (SCD-044) from Bioprojet for treatment of autoimmune disorders. SPARC acquired Bioprojet's rights for SCD-044 in December 2019.
• University of MichiganminorStrategic or Co-development PartnerResearch collaboration to evaluate anti-MUC-1 ADC in preclinical models.
• Tripoint TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerLicensed commercialization rights for Elepsia XR (levetiracetam ER tablets) 1000mg and 1500mg formulations for epilepsy treatment.
• Visiox PharmacoreOEM/ Whitelabel/ Licensing PartnerLicensed development and commercialization rights for PDP-716 (brimonidine) and SDN-037 (difluprednate) for ophthalmic indications.
• UCSF and Tiller TherapeuticsminorStrategic or Co-development PartnerSPARC announced signing of binding letter of intent with UCSF and Tiller Therapeutics in December 2024 for preclinical oncology asset and associated intellectual property.
• JHU and IOCBcoreStrategic or Co-development PartnerExclusive worldwide license agreement for SCD-153 with Johns Hopkins University (JHU) and Institute of Organic Chemistry and Biochemistry (IOCB). SCD-153 is a 4-methyl itaconate prodrug for alopecia areata treatment.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Biocon: Indian biopharmaceutical company developing innovative biologics and biosimilars with global licensing arrangements. Comparable as a clinical-to-commercial Indian biopharma with similar partnering model and innovation focus.
• Sun Pharmaceutical Industries: Parent company of SPARC and India's largest pharmaceutical company. Comparable as it commercializes SPARC's products and operates globally across generics and specialty, providing the parent-incumbent reference point for SPARC's potential value at scale.
• Glenmark Pharmaceuticals: Indian-headquartered global pharma with innovation pipeline in respiratory, oncology, and dermatology. Comparable as a domestic peer with proprietary R&D and licensing deals overlapping SPARC's therapeutic focus areas.
• Dr. Reddy's Laboratories: Large Indian pharmaceutical company with both generics and proprietary products. Comparable as a domestic public pharma peer with parallel global commercial footprint and innovation pipeline exposure.
• Piramal Pharma: Indian pharma company with innovation and CDMO businesses. Comparable as a domestic peer operating across drug development and commercial pharmaceutical services in overlapping therapeutic areas.

Direct peers

• Aurigene Oncology: India-based clinical-stage biotech focused on oncology and out-licensing candidates to global pharma. Closely comparable business model to SPARC: innovation-focused R&D, partnered commercialization, India cost base, oncology/immunology focus.
• Syngene International: India-based clinical research and biologics manufacturer. Comparable as a listed Indian biopharma services and innovation company leveraging Indian R&D cost advantage with global pharma partners.
• Suven Life Sciences: Indian clinical-stage biopharma developing CNS-focused novel therapeutics through licensing model. Comparable as a small-cap Indian innovator pursuing out-licensed drug development for global markets.

Regional players

• Natco Pharma: Indian pharma with innovation and specialty segments. Comparable as a domestic peer with proprietary drug development in oncology and complex generics alongside licensing activities.

Emerging players

• Concord Biotech: India-based biopharma with fermentation-based APIs and biosimilars. Comparable as a smaller, listed Indian biopharma operating in innovative drug development and licensing in adjacent therapeutic segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sun-pharma-advanced-research-company-ltd.
• Xx.com/sparcltd
• Facebookfacebook.com/Sun-Pharma-Advanced-Research-Center

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sun Pharma Advanced Research Company